A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
Trial Number
NCT03651206 (ClinicalTrials.gov Identifier)Contact Person
Status
Recruiting
Disease Site
Ovarian/Rare
Lead Cooperative Group
Participating Groups
GEICO
AGO
NCRI
MITO